✦ LIBER ✦

Palivizumab for RSV prophylaxis cost effective for high-risk infants

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness Analysis of Palivizum

✍ Langenfeld, M.K.; Visser, S. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Palivizumab's value for RSV prophylaxis

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB

Palivizumab's value for RSV prophylaxis

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB

Palivizumab for respiratory syncytial vi

✍ Jennifer H. Lofland; Suzanne M. Touch; John P. O'Connor; Mary Lou Chatterton; El 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 890 KB

Cost-Effectiveness Of Prophylaxis Of Res

✍ Rosselli, D.; Rueda, J.D.; Ruiz, J.G. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Palivizumab worth it for high-risk infan

📂 Article 📅 2002 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB